New blood pressure treatment tries fooling brain

December 7, 2012 by James Walsh, Star Tribune (Minneapolis)

While dozens of medical device makers are racing to treat medication-resistant hypertension by burning nerves inside arteries in the kidneys, Minneapolis firm CVRx is coming at the problem from a different direction.

Its implantable pacemaker-type device stimulates pressure sensors in the carotid arteries - essentially fooling the brain into . The system is minimally invasive, adjustable and reversible - and the results from it are dramatic, said CVRx President and CEO Nadim Yared.

"It's a beautiful system because, at the end of the day, we do not decide how to lower ," he said. "We let the brain decide."

The device has been approved to treat hypertension in Europe. CVRx is hoping to win U.S. approval. But CVRx also is hoping to show the U.S. Food and Drug Administration that its Barostim Neo device is safe and effective in treating as well. Early data are encouraging and clinical trials in Europe, Canada and the United States are continuing or getting underway, he said.

"It works," said Yared, who came to CVRx five years ago from GE Medical.

The human body has a system for sensing changes in blood pressure and other . While much of this system is located in the brain, there are also pressure sensors within the walls of the carotid arteries, in the neck that supply blood to the brain. Called baroreceptors, these sensors measure and report blood flow to the brain, which then make adjustments depending on the body's needs.

For example, higher blood pressure is good for exercising, while lower blood pressure is appropriate during sleep or other periods of reduced activity.

In much the same way that holding a match to the thermostat on the wall can make your home's furnace lower the heat, the Barostim Neo stimulates the baroreceptors to get the brain to lower blood pressure, Yared said.

A small device, like a pacemaker, is implanted under the . A thin wire runs from the device along the with an electrode about the size of the head of a nail. Doctors then use an external system to program and customize therapy settings.

Implanting the device usually takes an hour or two and can be done on an outpatient basis, although some patients stay overnight at the hospital.

Blood pressure is measured in millimeters of mercury (mm Hg) and recorded with the systolic number first, followed by the diastolic number. A normal blood pressure would be recorded as something under 120/80 mm Hg. About 1 in 3 American adults - nearly 70 million - have high blood pressure.

Yared said patients in the Barostim Neo studies have averaged a systolic pressure of 183; the device lowered the pressure of about half those patients to below 140.

Dr. Eric Irwin, a vascular surgeon at North Memorial Medical Center in Robbinsdale, Minn., has been involved with the CVRx technology for several years and holds stock options in the company.

"It is a big step forward," he said. "This has taken a group of patients who were 100 percent failing to respond to the best medical care and has gotten a 10-20 point drop in pressure. We're talking changes that are really significant."

At a time when med-tech giants Medtronic, St. Jude Medical and Boston Scientific are part of a stampede of firms developing renal denervation systems, Yared and others say CVRx might be on to a better approach. Renal denervation is a one-time treatment for hypertension in which a device burns - or ablates - nerves in the renal artery. That approach is available in Europe, although not yet in the United States.

But, Yared said, renal denervation is imprecise and irreversible. The Barostim Neo can be set at different stimulation settings for different times of the day and can be removed if necessary.

"This is more controllable and adjustable," Irwin said.

Said Yared: "We've had some patients and physicians who prefer the elegance of this approach."

Barostim Neo already is being sold for treating hypertension in Europe. CVRx is expected to earn about $2 million in 2012, Yared said. It continues to be studied for treating medication-resistant hypertension in the United States, as well as for treating heart failure in the United States, Canada and Europe. Yared said he expects the company to become profitable before FDA approval.

Thomas Gunderson, a senior analyst with Piper Jaffray Co., said its technology gives CVRx a unique place in the market for treating high blood pressure. In fact, the technology has even been shown to help patients for whom denervation was ineffective.

"When you see a big market opportunity with a clear benefit for the patients and the payers, you are going to have a lot of investment interest," he said of CVRx's potential.

The results of initial studies and earlier clinical trials have been promising enough that CVRx has to date attracted $209 million in financing and the enthusiastic support of venture capital firms New Enterprise Associates, or NEA, and Johnson & Johnson Development Corp.

Despite the uncertainties of the regulatory climate for medical devices, John Nehra, a special partner with NEA, said the large hypertension market - and CVRx's technology - makes it a good bet.

"We think the technology works," Nehra said. "Because of its programmability and adjustability, it works better than surgical intervention."

Nehra and Yared said the Barostim Neo could be approved for use in the United States in three or so years. In the meantime, Nehra said, a goal is for CVRx to reach $100 million in revenue in Europe and elsewhere.

"We feel very good about the company and its position," he said. "Although it has taken longer and more capital, the opportunity is still very much in front of us."

Explore further: Study tests new therapy for treatment-resistant hypertension

Related Stories

Study tests new therapy for treatment-resistant hypertension

June 28, 2012
(Medical Xpress) -- Treatment-resistant hypertension affects nearly 6 million Americans and another 94 million people worldwide and is associated with increased cardiovascular risk, including stroke and heart attack, as well ...

NY-Presbyterian Hospital announces participation in trial for hard-to-treat hypertension

October 25, 2012
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device ...

Renal denervation achieves significant and sustained blood pressure reduction

August 27, 2012
Renal denervation leads to significant and sustained blood pressure reduction for up to 18 months in patients with treatment resistant hypertension, according to research presented at ESC Congress 2012. The new clinical data ...

Canada's first renal denervation procedure to reduce high blood pressure performed today

January 17, 2012
Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada. The procedure can significantly reduce ...

Simple procedure lowers blood pressure in kidney disease patients

May 17, 2012
Disrupting certain nerves in the kidneys can safely and effectively lower blood pressure in patients with chronic kidney disease (CKD) and hypertension, according to a study appearing in an upcoming issue of the Journal of ...

Recommended for you

Sugar not so sweet for mental health

July 27, 2017
Sugar may be bad not only for your teeth and your waistline, but also your mental health, claimed a study Thursday that was met with scepticism by other experts.

Could insufficient sleep be adding centimeters to your waistline?

July 27, 2017
Adults in the UK who have poor sleep patterns are more likely to be overweight and obese and have poorer metabolic health, according to a new study.

Vitamin E-deficient embryos are cognitively impaired even after diet improves

July 27, 2017
Zebrafish deficient in vitamin E produce offspring beset by behavioral impairment and metabolic problems, new research at Oregon State University shows.

The role of dosage in assessing risk of hormone therapy for menopause

July 27, 2017
When it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered—taking a pill versus wearing a patch on one's skin—doesn't affect risk or benefit, researchers at UCLA and elsewhere ...

Blowing smoke? E-cigarettes might help smokers quit

July 26, 2017
People who used e-cigarettes were more likely to kick the habit than those who didn't, a new study found.

Brain disease seen in most football players in large report

July 25, 2017
Research on 202 former football players found evidence of a brain disease linked to repeated head blows in nearly all of them, from athletes in the National Football League, college and even high school.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.